Home > Rheumatology > ACR 2021 > Spotlight on Rheumatoid Arthritis > Ultra-low dosing of rituximab in RA is a viable treatment option

Ultra-low dosing of rituximab in RA is a viable treatment option

Presented By
Mr Nathan den Broeder, Sint Maartenskliniek, the Netherlands

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ACR 2021
Trial
REDO
Rituximab showed non-inferior efficacy of longer-term treatment of rheumatoid arthritis (RA) with an ultra-low dose. Dosing regimens of 500 mg and 200 mg led to comparable results to the 1,000 mg dose when following patients for up to 4 years. As rituximab was originally developed for lymphoma, special dose-finding investigations for RA are limited [1]. “The optimal dose of rituximab in RA is unknown,” said Mr Nathan den Broeder (Sint Maartenskliniek, the Netherlands) [1]. It has been however demonstrated that a low dose of 1,000 mg (or 2x500 mg) is equivalent to the registered high dose of 2x1,000 mg per 6 months [2]. Furthermore, the previous REDO trial (NTR6117) data showed on intention-to-treat analysis that an ultra-low dose of rituximab (i.e. 500 mg and 200 mg) was non-inferior to a standard low dose (1,000 mg) at 6 months, although the same conclusion failed in per-...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on